CN107531759B - 非膜破坏性p53活化装订肽 - Google Patents

非膜破坏性p53活化装订肽 Download PDF

Info

Publication number
CN107531759B
CN107531759B CN201680021720.3A CN201680021720A CN107531759B CN 107531759 B CN107531759 B CN 107531759B CN 201680021720 A CN201680021720 A CN 201680021720A CN 107531759 B CN107531759 B CN 107531759B
Authority
CN
China
Prior art keywords
peptide
xaa
alanine
pentenyl
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680021720.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107531759A (zh
Inventor
陈耀宸
克里斯托弗·约翰·布朗
钱德拉·S·韦尔马
F·J·费雷尔加戈
大卫·P·雷恩
T·约瑟夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science, Technology and Research
Original Assignee
Agency for Science, Technology and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science, Technology and Research filed Critical Agency for Science, Technology and Research
Publication of CN107531759A publication Critical patent/CN107531759A/zh
Application granted granted Critical
Publication of CN107531759B publication Critical patent/CN107531759B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680021720.3A 2015-02-13 2016-02-15 非膜破坏性p53活化装订肽 Active CN107531759B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201501119W 2015-02-13
SG10201501119W 2015-02-13
PCT/SG2016/050079 WO2016130092A1 (en) 2015-02-13 2016-02-15 Non-membrane disruptive p53 activating stapled peptides

Publications (2)

Publication Number Publication Date
CN107531759A CN107531759A (zh) 2018-01-02
CN107531759B true CN107531759B (zh) 2021-11-16

Family

ID=56614951

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680021720.3A Active CN107531759B (zh) 2015-02-13 2016-02-15 非膜破坏性p53活化装订肽

Country Status (6)

Country Link
US (1) US11319344B2 (enExample)
EP (1) EP3256484B1 (enExample)
JP (1) JP7028643B2 (enExample)
CN (1) CN107531759B (enExample)
SG (1) SG11201706562QA (enExample)
WO (1) WO2016130092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027585A2 (ko) * 2018-07-31 2020-02-06 주식회사 레모넥스 폴리펩타이드 전달용 조성물
CN121064336A (zh) * 2018-07-31 2025-12-05 雷莫内克斯生物制药有限公司 多肽递送组合物
WO2021112614A1 (ko) * 2019-12-05 2021-06-10 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 베체트병 또는 류마티스 관절염 예방 또는 치료용 약학조성물
CN111613275B (zh) * 2020-05-26 2021-03-16 中国海洋大学 一种基于rmsd多特征的药物分子动力学结果分析方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
WO2022081827A1 (en) 2020-10-14 2022-04-21 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2024051616A1 (zh) * 2022-09-09 2024-03-14 湖南大学 一种多肽及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149339A2 (en) * 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
WO2014055039A1 (en) * 2012-10-01 2014-04-10 Agency For Science, Technology And Research Peptides and methods for treating cancer
WO2014159969A1 (en) * 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2583876C2 (ru) * 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
US20120328692A1 (en) * 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
US20150010932A1 (en) 2013-07-02 2015-01-08 Salk Institute For Biological Studies Methods for assaying protein-protein interactions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149339A2 (en) * 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
WO2014055039A1 (en) * 2012-10-01 2014-04-10 Agency For Science, Technology And Research Peptides and methods for treating cancer
WO2014159969A1 (en) * 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof

Also Published As

Publication number Publication date
EP3256484A4 (en) 2018-07-25
JP2018507689A (ja) 2018-03-22
EP3256484A1 (en) 2017-12-20
US11319344B2 (en) 2022-05-03
EP3256484B1 (en) 2021-06-23
WO2016130092A1 (en) 2016-08-18
JP7028643B2 (ja) 2022-03-02
SG11201706562QA (en) 2017-09-28
US20180030090A1 (en) 2018-02-01
CN107531759A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
US11319344B2 (en) Non-membrane disruptive P53 activating stapled peptides
Peraro et al. Diversity-oriented stapling yields intrinsically cell-penetrant inducers of autophagy
JP6966996B2 (ja) Ｐｃｎａ阻害剤
JP2020514254A (ja) がん治療のための組成物および方法
EP3442991A1 (en) Ras binding peptides and methods of use
JP2014520120A (ja) 安定化した変異型ｍａｍｌペプチドおよびその使用
WO2019094830A1 (en) Mitofusin modulation agents and methods of use thereof
JP2025509290A (ja) Ｐｃｎａ阻害剤及びその使用
Wang et al. Discovery and identification of Cdc37-derived peptides targeting the Hsp90–Cdc37 protein–protein interaction
Li et al. Discovery and development of NLRP3 inhibitors targeting the LRR domain to disrupt NLRP3-NEK7 interaction for the treatment of rheumatoid arthritis
AU2018383633B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
US20150246946A1 (en) Peptides and methods for treating cancer
WO2010132869A2 (en) Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
US20160046672A1 (en) STAPLING eIF4E INTERACTING PEPTIDES
EP3986438B1 (en) P53 activator peptidomimetic macrocycles
JP6566947B2 (ja) Ｍａｐキナーゼｐ３８結合化合物
CN115697331A (zh) Taspase1抑制剂及其用途
JP2024501019A (ja) Ｓｏｓの架橋ヘリックス二量体模倣体およびそれを使用する方法
CN116234541A (zh) 通过EpoR拮抗剂治疗疾病
EP4076416A1 (en) Small-molecule covalent inhibition of ral gtpases
US20230399361A1 (en) Macrocyclic peptides
Pan Discovering small molecule inhibitors targeted to ligand-stimulated RAGE-DIAPH1 signaling transduction
Srdanovic Modulation of protein-protein interactions in the p53 pathway
WO2023069332A1 (en) Cell permeable macrocyclic peptides useful for eif4e cap-binding site inhibition
KR20230074784A (ko) 아릴피롤 유도체의 약학적 염

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant